[P14] Human Apolipoprotein CIII (Apo CIII), Academy Bio-medical Company, Inc.

[P14] Human Apolipoprotein CIII (Apo CIII)

33P-102

Academy Bio-Medical Company, Inc.

  • $221.00


Concentration: 1 mg / ml, determined by the Lowry method
Source: From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.
Purification: After series ultracentrifugations, Very Low Density Lipoprotein (VLDL) is isolated from human plasma. Apo CIII is purified from delepidated VLDL, followed by gel-filtration and DEAE-Sepharcyl chromatography. Minor impurities of other apo-proteins are then removed by antibody-Sepharose™ affinity column.
Purity: ≥ 98% by SDS-PAGE
Buffer: In 10 mM Tris-HCl, 0.15 M NaC1, 0.5 mM EDTA, 0.02 % NaN3, pH 8.0
Storage: -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

 

Citations

 

[P14][P15] 2017 Toth, Christopher A.; Kuklenyik, Zsuzsanna; Jones, Jeffrey I.; Parks, Bryan A.; Gardner, Michael S.; Schieltz, David M. et al. (2017): On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. In Journal of proteomics 150, pp. 258–267. DOI: 10.1016/j.jprot.2016.09.011.
[P14][P15] 2016 Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of lipid research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816.
[P14][P15] 2013 Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271.
[P14][P15] 2011 Holleboom, Adriaan G.; Karlsson, Helen; Lin, Ruei-Shiuan; Beres, Thomas M.; Sierts, Jeroen A.; Herman, Daniel S. et al. (2011): Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man. In Cell metabolism 14 (6), pp. 811–818. DOI: 10.1016/j.cmet.2011.11.005.
[P14][P15] 2010 Abe, Yasuko; Kawakami, Akio; Osaka, Mizuko; Uematsu, Satoshi; Akira, Shizuo; Shimokado, Kentaro et al. (2010): Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. In Arterioscler Thromb Vasc Biol. 30 (11), pp. 2242–2248. DOI: 10.1161/ATVBAHA.110.210427.
[P14][P15] 2010 Mazur, Matthew T.; Cardasis, Helene L.; Spellman, Daniel S.; Liaw, Andy; Yates, Nathan A.; Hendrickson, Ronald C. (2010): Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. In Proc Natl Acad Sci USA 107 (17), pp. 7728–7733. DOI: 10.1073/pnas.0910776107.
[P14][P15] 2007 Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[P14][P15] 2007 Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[P14][P15] 2006 Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514.
[P14][P15] 2006 Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[P14][P15] 2006 Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200.
[P14][P15] 2005 Gerritsen, Gery; Rensen, Patrick C. N.; Kypreos, Kyriakos E.; Zannis, Vassilis I.; Havekes, Louis M.; van Willems Dijk, Ko (2005): ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. In J. Lipid Res. 46 (7), pp. 1466–1473. DOI: 10.1194/jlr.M400479-JLR200.
[P14][P15] 2002 Olin-Lewis, Katherine; Krauss, Ronald M.; La Belle, Michael; Blanche, Patricia J.; Barrett, P. Hugh R.; Wight, Thomas N.; Chait, Alan (2002): ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. In J. Lipid Res. 43 (11), pp. 1969–1977. DOI: 10.1194/jlr.M200322-JLR200.

We Also Recommend